Clinical trials: Advanced Adult Hepatocellular Carcinoma
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Hepatocellular Carcinoma, Hepatoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT04567615
- Testing
- Nivolumab, Relatlimab
- Where
- 65 sites in Argentina, Brazil and 15 more
- Volunteers
- 266 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Advanced Adult Hepatocellular Carcinoma
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer worldwide and the third most common cause of death from cancer.
- Trial name
- G-202-003 (NCT01777594)
- Testing
- G-202
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- GenSpera, Inc.
Hepatocellular Carcinoma, Liver Cancer
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
- Trial name
- ET-109 (NCT03998033)
- Testing
- ET140202 autologous T cell product
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Eureka Therapeutics Inc.
Soft Tissue Sarcoma, Renal Cell Carcinoma
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study.
- Conditions
- Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma
- Trial name
- NCT05229601
- Testing
- HFB301001
- Where
- 10 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- HiFiBiO Therapeutics
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Advanced Adult Hepatocellular Carcinoma
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and tolerability of dalantercept plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose level of dalantercept in combination…
- Trial name
- NCT02024087
- Testing
- Dalantercept plus sorafenib
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hepatocellular Carcinoma
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
- Trial name
- ATHENA (NCT06084884)
- Testing
- AZD5851
- Where
- 19 sites in United States, Japan and 1 more
- Volunteers
- 94 people
- Sponsor
- AstraZeneca
Advanced Hepatocellular Carcinoma
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
This study is establish whether INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway and whose disease progressed while on, or after, treatment…
- Trial name
- NCT01964235
- Testing
- INC280
- Where
- 15 sites in United States, Australia and 5 more
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.
- Trial name
- NCT01839604
- Testing
- AZD9150
- Where
- 7 sites in Hong Kong, Japan and 2 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in…
- Trial name
- NCT06478693
- Testing
- MT-303, MT-303 +Atezolizumab + Bevacizumab
- Where
- 9 sites in Australia, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Myeloid Therapeutics
Metastatic Hepatocellular Carcinoma, Solid Tumors
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic…
- Conditions
- Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
- Trial name
- SURF431 (NCT06915753)
- Testing
- TYRA-430
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 125 people
- Sponsor
- Tyra Biosciences, Inc
Hepatocellular Carcinoma, Liver Cancer, Adult
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT05195294
- Testing
- LioCyx-M, Lenvatinib
- Volunteers
- 55 people
- Sponsor
- Lion TCR Pte. Ltd.
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Advanced Adult Hepatocellular Carcinoma
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
Treatment options for advanced hepatocellular carcinoma (HCC) are limited due to patients' poor condition, advanced tumor, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy.
- Trial name
- NCT02418988
- Testing
- TACE plus rAd-p53 artery injection, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals